Acrux Ltd: Appendix 4G and Corporate Governance Statement FY24
Acrux Ltd: FDA Approval received for Dapsone Gel, 7.5%
Acrux Ltd: Quarterly Activities Report and Appendix 4C - June 2024
Acrux Ltd: RDTI funding facility secured
Acrux Ltd: Quarterly Activities and Appendix 4C, reissued
Acrux Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Acrux Ltd: Launch of Dapsone 5%, Gel in the United States
Acrux Ltd: Appendix 3Y Dobinson
Acrux Ltd: Appendix 3Y Brumley
Acrux Ltd: Investor Webinar Details - Financial Results 1H FY24
Acrux Ltd: Appendix 4C and Activities Statement
Acrux Ltd: Appendix 3Y Oldham
Acrux Ltd: Appendix 3Y Brooke
Acrux Ltd: Appendix 3Y Oldham
Acrux Ltd: Appendix 3Y Dobinson
Acrux Ltd: Appendix 3Y Brumley
Acrux Ltd: Appendix 3Y Brooke
Acrux Ltd: Address of Chair and CEO to AGM
Acrux Ltd: Appendix 3Y Dobinson
Acrux Ltd: Appendix 3Y Brumley
No Data
No Data